Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6Head & Neck 2Gastrointestinal 2Thoracic 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 101Endometrial Neoplasms 74Uterine Cervical Neoplasms 63Carcinoma, Non-Small-Cell Lung 56Colorectal Neoplasms 50Melanoma 49Triple Negative Breast Neoplasms 42Carcinoma, Renal Cell 41Stomach Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Fallopian Tube Neoplasms 33Breast Neoplasms 33Pancreatic Neoplasms 27Neoplasms 25Esophageal Neoplasms 24Carcinoma, Transitional Cell 24Neoplasm Metastasis 23Carcinoma, Hepatocellular 20Lung Neoplasms 19Carcinoma, Ovarian Epithelial 19Small Cell Lung Carcinoma 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 17Prostatic Neoplasms 14Cholangiocarcinoma 13Carcinoma, Merkel Cell 11Kidney Neoplasms 10Mesothelioma 9Uterine Neoplasms 8

Interventions

Doxorubicin 4Ifosfamide 3Radiotherapy 2Ipilimumab 2Filgrastim 2saracatinib 1perifosine 1pembrolizumab 1fludarabine 1brostallicin 1belinostat 1aldesleukin 1Trabectedin 1Temozolomide 1Sunitinib 1Ritonavir 1Nivolumab 1Mass Spectrometry 1Injections 1Indinavir 1Imatinib Mesylate 1Fluorouracil 1Cyclophosphamide 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × pembrolizumab × Gynecologic × Clear all
NCT04099277 2021-08-31

A Study of LY3435151 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
2 enrolled 8 charts
BreastGastrointestinalGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡